Cattaneo D - Search Results

1

Does lopinavir really inhibit SARS-CoV-2?

Cattaneo D, Cattaneo D, Gervasoni C, Corbellino M, Galli M, Riva A, Gervasoni C, Clementi E, Clementi E. Cattaneo D, et al. Pharmacol Res. 2020 Aug;158:104898. doi: 10.1016/j.phrs.2020.104898. Epub 2020 May 11. Pharmacol Res. 2020. PMID: 32438034 Free PMC article.

2

Determination of linezolid in human plasma by high-performance liquid chromatography with ultraviolet detection.

Cattaneo D, Baldelli S, Conti F, Cozzi V, Clementi E. Cattaneo D, et al. Ther Drug Monit. 2010 Aug;32(4):520-4. doi: 10.1097/FTD.0b013e3181d5eeee. Ther Drug Monit. 2010. PMID: 20300050

3

Co-administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humans.

Sciorati C, Buono R, Azzoni E, Casati S, Ciuffreda P, D'Angelo G, Cattaneo D, Brunelli S, Clementi E. Sciorati C, et al. Among authors: d angelo g, cattaneo d. Br J Pharmacol. 2010 Jul;160(6):1550-60. doi: 10.1111/j.1476-5381.2010.00809.x. Br J Pharmacol. 2010. PMID: 20590643 Free PMC article.

4

Clinical pharmacokinetics of ibuprofen arginine.

Cattaneo D, Clementi E. Cattaneo D, et al. Curr Clin Pharmacol. 2010 Nov;5(4):239-45. doi: 10.2174/157488410793352012. Curr Clin Pharmacol. 2010. PMID: 20925647 Review.

5

Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients.

Cattaneo D, Ripamonti D, Baldelli S, Cozzi V, Conti F, Clementi E. Cattaneo D, et al. Ther Drug Monit. 2010 Dec;32(6):782-6. doi: 10.1097/FTD.0b013e3181fa53b7. Ther Drug Monit. 2010. PMID: 20926993

6

Virologic failure in an HIV-infected woman given desogestrel for excessive menstrual bleeding.

Cattaneo D, Meraviglia P, Beretta R, Baldelli S, Cozzi V, Milani G, Clementi E. Cattaneo D, et al. Eur J Clin Pharmacol. 2011 Apr;67(4):429-431. doi: 10.1007/s00228-010-0934-y. Epub 2010 Nov 3. Eur J Clin Pharmacol. 2011. PMID: 21046092 No abstract available.

7

Atypical pharmacokinetics of atazanavir in an HIV-1-infected patient.

Cattaneo D, Meraviglia P, Cozzi V, Baldelli S, Milani G, Clementi E. Cattaneo D, et al. Fundam Clin Pharmacol. 2012 Apr;26(2):204-6. doi: 10.1111/j.1472-8206.2010.00905.x. Epub 2011 Jan 7. Fundam Clin Pharmacol. 2012. PMID: 21210843

8

Limited sampling strategies for the estimation of raltegravir daily exposure in HIV-infected patients.

Cattaneo D, Ripamonti D, Gervasoni C, Landonio S, Meraviglia P, Baldelli S, Cozzi V, Fucile S, Clementi E. Cattaneo D, et al. J Clin Pharmacol. 2012 Mar;52(3):440-5. doi: 10.1177/0091270010395939. Epub 2011 Mar 7. J Clin Pharmacol. 2012. PMID: 21383337

9

Reply to 'Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients'.

Cattaneo D, Gervasoni C. Cattaneo D, et al. AIDS. 2011 Apr 24;25(7):1012-3; author reply 1011-2. doi: 10.1097/QAD.0b013e3283463c84. AIDS. 2011. PMID: 21412129 No abstract available.

10

A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy.

Sciorati C, Miglietta D, Buono R, Pisa V, Cattaneo D, Azzoni E, Brunelli S, Clementi E. Sciorati C, et al. Among authors: cattaneo d. Pharmacol Res. 2011 Sep;64(3):210-7. doi: 10.1016/j.phrs.2011.05.003. Epub 2011 May 12. Pharmacol Res. 2011. PMID: 21609764 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

607 results

Search Page